Source: Annual Congress 2010 - Does cost-effectiveness go together with best quality of treatment? New drivers in medicine
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
N. Mittmann, P. Hernandez, C. Mellström, L. Brannman, T. Welte (Halifax, Canada; Lund, Sweden; , Germany). Cost-effectiveness of budesonide/formoterol added to tiotropium in COPD patients in Canada, Australia and Sweden. Eur Respir J 2010; 36: Suppl. 54, 5183

Member's Comments

No comment yet.

Related content which might interest you: Cost-effectiveness of adding budesonide/formoterol to tiotropium in severe COPD patients in four Nordic countries Source: Annual Congress 2012 - COPD treatments: efficacy and safety Year: 2012 Economic evaluation of beclomethasone/formoterol versus budesonide/formoterol in the treatment of patient with moderate-severe asthma in Spain Source: Annual Congress 2008 - Impact of patient education on cost-effectiveness of treatment Year: 2008 Real-life evaluation of budesonide/formoterol (DuoResp Spiromax) for the management of asthma and COPD in the UK Source: International Congress 2017 – Primary care diagnosis, assessment and management of COPD Year: 2017 The TORCH (TOwards a Revolution in COPD Health) study: salmeterol/ fluticasone propionate (SFC) is well tolerated in patients with COPD over three years Source: Eur Respir J 2006; 28: Suppl. 50, 34s Year: 2006 Cost-effectiveness of tiotropium versus glycopyrronium in moderate to very severe COPD in France Source: International Congress 2017 – Does economisation of medicine transfer into benefits for patients? Year: 2017 Benefit of budesonide/formoterol compared with salmeterol/fluticasone in COPD patients in the morning Source: Annual Congress 2009 - Healthcare and treatment of COPD Year: 2009 Economic evaluation of salmeterol/fluticasone propionate combination vs budesonide/formoterol in Spain Source: Annual Congress 2003 - Management of asthma in primary care Year: 2003 Pharmacoeconomic analysis of beclomethasone/formoterol versus fluticasone/salmeterol in the treatment of moderate-severe asthma in Spain Source: Annual Congress 2008 - Impact of patient education on cost-effectiveness of treatment Year: 2008 The occurrence of pneumonia in COPD patients treated with salmeterol xinafoate 50mcg/fluticasone propionate 250mcg (SFC250) – Interim report of post-marketing surveillance in Japan Source: Annual Congress 2012 - COPD treatment and varia Year: 2012 Efficacy and safety of extrafine glycopyrronium bromide pMDI (CHF 5259) in COPD patients Source: International Congress 2016 – Novel avenues in the treatment of COPD I Year: 2016 A UK based cost-utility analysis of indacaterol – A once-daily maintenance bronchodilator for patients with COPD Source: Annual Congress 2012 - Looking at the cost effectiveness of asthma and COPD treatment by novel drugs and improved management Year: 2012 Economic evaluation of salmeterol/fluticasone combination versus budesonide plus formoterol in Spain Source: Eur Respir J 2001; 18: Suppl. 33, 49s Year: 2001 Safety and efficacy of fluticasone furoate/vilanterol trifenatate (FFVI) in COPD patients Source: Annual Congress 2010 - Bronchodilators in airways disease Year: 2010 Asthma exacerbations in children receiving montelukast vs. other controllers in Italy Source: Eur Respir J 2005; 26: Suppl. 49, 618s Year: 2005 Safety of tiotropium and olodaterol fixed-dose combination for COPD in patients on β-blockers Source: International Congress 2015 – New data on established treatments for COPD Year: 2015 Efficacy of tiotropium and olodaterol fixed-dose combination in patients with COPD on β-blockers Source: International Congress 2015 – Safety of and interactions between current treatments for asthma and COPD Year: 2015 Modelling the 5-year cost-effectiveness of tiotropium, salmeterol and ipratropium for the treatment of chronic obstructive pulmonary disease (COPD) in Spain Source: Eur Respir J 2006; 28: Suppl. 50, 683s Year: 2006 The TORCH (TOwards a Revolution in COPD Health) study: salmeterol/fluticasone propionate (SFC) improves survival in COPD over three years Source: Eur Respir J 2006; 28: Suppl. 50, 34s Year: 2006 The efficacy of salmeterol xinafoate (SX) in the treatment of COPD during 6-month‘s in conditions of Eastern Siberia (ES) Source: Eur Respir J 2004; 24: Suppl. 48, 289s Year: 2004 Clinical effects of adding fluticasone propionate/salmeterol (FSC) and tiotropium (TIO) in severe-to-very severe COPD Source: Annual Congress 2005 - Therapeutic options for COPD: present and future Year: 2005